(Q33924148)

30 July 2017

1 reference

title

The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression (English)

1 reference

30 July 2017

Jann MW

1

1 reference

30 July 2017

Cohen LJ

series ordinal

2

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Drug Metabolism and Drug Interactions

30 July 2017

published in

1 reference

30 July 2017

volume

16

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

39-67

1 reference

The global burden of mental disorders.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Clinical trials and transethnic pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Genetically determined adverse drug reactions involving metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Genetically determined variability in acetylation and oxidation. Therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Pharmacokinetics of the newer antidepressants: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Citalopram in the treatment of depression and other potential uses in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Drug interactions of clinical significance with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

Antidepressant interactions with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2000.16.1.39

10.1515/DMDI.2000.16.1.39

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference